Ajanta Pharma Q1 FY27 Results Analysis: US Generics Surge 57%, Asia Generics Decline 16% (AJANTPHARM)

Ajanta Pharma Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 1,625.96 Cr (+24.82% YoY) and PAT growth of +30.89% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

Ajanta Pharma delivered a strong Q1 with 24.8% revenue growth and 30.9% PAT growth, driven by a massive 57% surge in US generics (far above guidance) and India branded generics outperforming the market. However, Asia branded generics declined 16% (missed guidance) and the effective tax rate rose. The company's adjusted EBITDA margin of 28.0% was within guidance, and the dividend was raised. Overall, a solid quarter with a key growth surprise in US, but Asia remains a concern.

Key Investment Insights

Key Positives

• Revenue grew 24.8% YoY to Rs.1,625.96 Cr, highest quarterly growth in at least five quarters.
• PAT grew 30.89% YoY to Rs.334.22 Cr, EPS at Rs.26.75.
• US Generics revenue grew 57% YoY, far exceeding management's mid-single-digit guidance.
• India branded generics grew 24% YoY, outperforming IPM growth of 11%.
• Adjusted EBITDA margin of 28.0% was within the guided band of 27%±1%.
• Interim dividend raised to Rs.32 per share from Rs.28 per share.
• 3 ANDA approvals received in Q1, with 2 launched.

Risk Factors

• Asia branded generics declined 16% YoY, missing management's low double-digit growth guidance.
• Effective tax rate rose to 25.20% from 22.89% in Q1 FY26 due to one manufacturing facility transitioning out of tax exemption.
• Forex volatility remains lumpy; net gain this quarter but reported EBITDA margin compressed 92 bps YoY to 26.05% due to forex losses.